¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Drug Screening Assays, Antitumor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® screening ÇÑ±Û °Ë»ö, ¼±º°
¼³¸í   
  1. º¸±â¿¡´Â °Ç°­ÇÑ °Í°ú °°ÀÌ º¸À̸鼭 Áúº´¿¡ °É·ÁÀÖ´Ù°í »ý°¢µÇ´Â »ç¶÷µéÀ» °ñ¶ó³»±â À§ÇÑ °Ë»ç. Áúº´ÀÇ Áø´ÜÀ» ÀǵµÇÑ °ÍÀº ¾Æ´Ï°í ´Ù¼öÀÇ ¼öÀüÀÚ Áß¿¡¼­ ºñ±³Àû °£´ÜÇÑ ¹æ¹ýÀ¸·Î ÀǽÉÀÌ °¡´Â ÀÚ¸¦ °ñ¶ó³»´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÑ´Ù. ¼±ÃâµÈ Àڴ ´õ¿í »ó¼¼ÇÑ °Ë»ç¸¦ ¹ÞÀ» Çʿ䰡 ÀÖ´Ù. 2. ½ÃÇèÀ̳ª °Ë»ç¿Í °°Àº ¿¹ºñÀû ÀýÂ÷, Á¶»ç°¡ ´õ ÇÊ¿äÇÑ Àå¾ÖÀÇ °¡Àå Æ¯Â¡ÀûÀΠ¡Èĸ¦ Ã£¾Æ³»±â À§ÇØ ½ÃÇàÇÑ´Ù. 3. Áý´Ü¼±º°°Ë»ç, °íÇ÷¾Ð°ú °°Àº Æ¯Á¤º´À̳ª Àå¾Ö¸¦ Ã£¾Æ³»±â À§ÇØ Å« Ç¥º»À» ÀÌ¿ëÇϴ °Ë»ç.
¿µ¹® antihypertensive drug ÇÑ±Û °íÇ÷¾Ð¾à, Ç×°íÇ÷¾ÐÁ¦
¼³¸í   
  °íÇ÷¾ÐÀÇ Ä¡·á¿¡ »ç¿ëÇϸ砳ôÀº Ç÷¾ÐÀ» ³·Ãߴ ¾à¹°À» ¸»ÇÑ´Ù. °íÇ÷¾Ð¾à¿¡´Â Ç÷°üÆòȰ±Ù¿¡ Á÷Á¢ ÀÛ¿ëÇÏ¿© À̿ϽÃ۴ Ç÷°üÈ®ÀåÁ¦(È÷µå¶ó¶óÁø), ±³°¨½Å°æÀǠȰµ¿À» ¾îµð¼±°¡ Â÷´ÜÇϴ ¾à¹°(·¹¼¼¸£ÇÉ, ¸ÞÆ¿µµÆÄ, ÇÁ·ÎÇÁ¶ó³ë·Ñ), ÀÌ´¢Á¦(ÇÁ·Î¼¼¹Ìµå, ¿¡Å¸Å©¸°»ê)ÀÌ »ç¿ëµÈ´Ù.
¿µ¹® antimalarial drug ÇÑ±Û ¸»¶ó¸®¾Æ¾à, Ç׸»¶ó¸®¾ÆÁ¦
¼³¸í   
  ¸»¶ó¸®¾Æ Ä¡·á¿¡ ¾²´Â ¾à. Å°´Ï³×, Å¬·Î·ÎÄý, ÇÁ¸®¸¶Äý µûÀ§°¡ ÀÖ´Ù. ¸»¶ó¸®¾Æ ¿øÃæÀÇ ¹ßÀ°Áֱ⿡ ´ëÀÀÇØ¼­ ¾à¹°ÀÌ ÀÖÀ¸³ª ´ëºÎºÐÀº º´¿ë¿ä¹ý¿¡ µû¶ó¼­ ¸»¶ó¸®¾Æ Ä¡·á¸¦ ÇÑ´Ù. ¸ð±â¿¡ ÀÇÇÑ Æ÷ÀÚü°¨¿°¿¡ ´ëÇÑ Çׯ÷ÀÚü ¾àÀº µ¶¼º µîÀÇ ¹®Á¦°¡ À־ ¾ÆÁ÷ ¾ø´Ù. ÀûÇ÷±¸³»¿¡¼­ÀǠȯ»óü, ¹ø½Äü¿¡¸¸ ÀÛ¿ëÇϴ °Í(Ç×¹ø½Äü ¾àÀº Å¬·Î·ÎÄý, ÇǸ®¸ÞŸ¹Î, Å¬·Î·Î±¸¾Æ³ªÀ̵å, Å°´Ï³×)Àº ÀûÇ÷±¸ ¿ÜÀÇ ¹ßÀ°Àº ¾ïÁ¦ÇÏÁö ¾ÊÀ¸¹Ç·Î °¨¿°À» ¿ÏÀüÈ÷ ÀúÁöµÇÁö ¾Ê´Â´Ù. ÀûÇ÷±¸³»¿ÜÀÇ ¿øÃæ¿¡ ÀÛ¿ëÇØ ¿ÏÀüÈ÷ °¨¿°À» ¾ïÁ¦Çϴ °Í(ÆÄ¸¶Å², ÆæÅ¸Å², ÇÁ¸®¸¶Å²), Ç÷ÁßÀÇ »ý½Äü¸¦ Á×À̴ °Í(´ëºÎºÐÀÇ Ç׸»¶ó¸®¾ÆÁ¦)Àº ¸ð±â¿¡ ÀÇÇѠŸÀÎÀ¸·ÎÀÇ Àü¿°¿øÀº ²÷±â´Âµ¥ È¯ÀÚÀÚ½ÅÀÇ Áõ»óÀº º¯È­ÇÏÁö ¾Ê´Â´Ù.
¿µ¹® drug ÇÑ±Û ¾à, ¾à¹°, ¾àÁ¦
¼³¸í   
  1. º´, ±âŸ º´Àû »óÅÂÀÇ Áø´Ü, Ä¡·á, ¿¹¹æÀ̳ª °íÅëÀÇ °æ°¨, ¶Ç´Â »ý¸®Àû, º´¸®Àû »óŸ¦ È£Àü½Ã۴ °ÍÀ» ¸ñÀûÀ¸·Î »ç¶÷ ¶Ç´Â µ¿¹°¿¡ Åõ¿©µÇ´Â È­ÇÕ¹°. ¾à¸®Çп¡¼­´Â Ä¡·á¾à¸¸ÀÌ ¾Æ´Ï¶ó, »ýü¿¡ ÁÖ¾îÁ³À» ¶§ ¾î¶°ÇÑ ¹ÝÀÀÀ» ³ªÅ¸³»´Â È­Çй°Áú ¸ðµÎ¸¦ ¾à¹°À̶ó°í ÇÑ´Ù. ÀÛ¿ëÀÌ °­ÇÏ°í ¾ÈÀü¼ºÀÌ ³·Àº ¼ø¼­·Î µ¶¾à-±Ø¾à-º¸Åë¾àÀ¸·Î ±¸ºÐÇϰí ÀÖ´Ù. ¾à¹°Ä¡·á¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÎÀڷμ­, »ýüÂÊ ÀÎÀڷδ °³Ã¼Â÷, ¿¬·É, Ã¼Áß µîÀÌ ÀÖ°í, ¾à¹°ÂÊ ÀÎÀڷμ­´Â Åõ¿©¹æ¹ý, Åõ¿©·®, º´¿ëµÇ°í Àִ ´Ù¸¥ ¾à¹° µîÀÌ ÀÖ´Ù. 2. ¾àÀÇ Àç·á°¡ µÇ´Â ¹°Áú. 3. ¿©·¯ °¡Áö ¾àÀ縦 ¼¯¾î Á¶Á¦ÇÑ ¾à.
¿µ¹® drug resistance ÇÑ±Û ¾à¹°³»¼º
¼³¸í   
  1. È­Çпä¹ýÁ¦³ª Ç×»ý¹°ÁúÀÇ ¾î¶² ÀÏÁ¤ ³óµµ·Î ¼¼±ÕÀ» Á×À̰ųª Áõ½ÄÀúÇØ¸¦ ¹Þ´Â °ÍÀ» ÀÌ È­Çпä¹ýÁ¦³ª Ç×»ý¹°Áú¿¡ °¨¼ö¼ºÀÌ ÀÖ´Ù°í Çϴµ¥, ÀÌ °¨¼ö¼ºÀÌ ¾ø°Ô µÈ »ýŸ¦ ÀúÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. µû¶ó¼­ º¯À̹̻ý¹°ÀÇ ¾àÁ¦¿¡ ´ëÇÑ ÀÚÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. 2. ÀǾàǰÀ» °è¼Ó º¹¿ëÇϸé Á¡Â÷ Áõ·®ÇÏÁö ¾ÊÀ¸¸é È¿·ÂÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¼ºÁú. ÀÌ·¯ÇÑ ¶§¸¦ ¾àÁ¦³»¼ºÀÌ »ý°å´Ù°í ÇÑ´Ù. ¸ðµç ¹Ì»ý¹°Àº °¨¼ö¼ºÀ» °¡Áö´Â ¾à¹°¿¡ ÀÇÇÏ¿© »ç¸êµÇÁö¸¸, ¼Ò¼öÀÇ °ÍÀº »ì¾Æ³²¾Æ ±×°ÍÀÌ ÁøÈ­µÊÀ¸·Î½á »ç¸êÇÏÁö ¾Ê´Â ¼ö°¡ ÀÖ´Ù. ¶Ç, ÃÖÃÊ¿¡´Â °¨¼ö¼ºÀ» °¡Áö°í ÀÖ´ø ±ÕÀÌ Â÷Â÷ ³»¼º±ÕÀ¸·Î µÇ±âµµ ÇÑ´Ù. ¸¹Àº º´¿ø±ÕÀº °¨¼ö¼ºÀÌ Àִ ÀǾàǰ¿¡ ´ëÇÏ¿© ³»¼ºÀÌ »ý±ä´Ù. °¡Àå °íµµÀÇ ³»¼º±ÕÀÌ »ý±â±â ½¬¿î °ÍÀº ½ºÆ®·¾Å丶À̽ÅÀε¥ °áÇÙ±Õ°ú ±×¶÷À½¼º±Õ¿¡ ´ëÇÏ¿© ½±°Ô ³»¼ºÀÌ »ý±ä´Ù. Æä´Ï½Ç¸°À̳ª Åׯ®¶ó½ÃŬ¸°(¾ÆÅ©·Î¸¶À̽Å) µîÀÇ Ç×»ý¹°Áúµµ ³»¼ºÀÌ »ý±â±â ½¬¿ì¹Ç·Î, »ç¿ëÇÒ ¶§´Â ÀûÀÀÀ» Àß È®ÀÎÇÏ¿© Çʿ䷮À» Á¤ÇÏ°í ¿¬¿ëÀ» ÇÇÇÑ´Ù. °°Àº È¿°ú°¡ Àִ ´Ù¸¥ Á¾·ùÀÇ ¾àÁ¦¸¦ ¼Ò·®¾¿ 2, 3Á¾ º´¿ëÇϸ頳»¼ºÀÇ ¹ß»ýÀÌ Å©°Ô ¾ïÁ¦µÈ´Ù´Â °ÍÀÌ ¾Ë·ÁÁ® ÀÖ´Ù. °áÇÙ¾àÀ¸·Î¼­ ½ºÆ®·¾Å丶À̽Űú ÆÄ½º, ¶Ç´Â À̼ҴϾÆÁöµå¸¦ º´¿ëÇϴ °Í µîÀÌ ±× ¿¹ÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antitumor agent
    Ç×¾ÏÁ¦
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • Denver Developmental Screening Test
    µ§¹ö¹ß´Þ¼±º°°Ë»ç
  • genetic screening
    À¯Àü¼±º°°Ë»ç
  • health screening
    °Ç°­Áø´Ü°Ë»ç, °Ç°­¼±º°°Ë»ç
  • multiphasic screening
    ´Ù»ó¼±º°°Ë»ç
  • mass screening
    Áý´Ü¼±º°°Ë»ç
  • maternal serum screening
    ¸ðüÇ÷û¼±º°°Ë»ç
  • neonatal screening
    ½Å»ý¾Æ¼±º°°Ë»ç
  • prescriptive screening
    ó¹æÀû¼±º°°Ë»ç
  • screening
    °Ë»ö, ¼±º°°Ë»ç
  • screening program
    Áý´Ü°ËÁø»ç¾÷, À¯¼Ò°ßÀڹ߰߻ç¾÷
  • screening test
    ¼±º°°Ë»ç
  • antiallergic drug
    ¾Ë·¹¸£±â¾à, Ç׾˷¹¸£±âÁ¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antitumor agent
    Ç×¾ÏÁ¦
  • screening
    °Ë»ö, ¼±º°, °Ë»ç
  • neonatal screening
    ½Å»ý¾Æ¼±º°°Ë»ç
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • screening test
    ¼±º°°Ë»ç
  • drug
    ¾à, ¾à¹°, ¾àÁ¦
  • antiamebic drug
    ¾Æ¸Þ¹Ù¾à, Ç׾Ƹ޹ÙÁ¦
  • antiarrhythmic drug
    ºÎÁ¤¸Æ¾à, Ç׺ÎÁ¤¸ÆÁ¦
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦
  • antiemetic drug
    ±¸Åä¾à, Ç×±¸ÅäÁ¦
  • antihistaminic drug
    Ç×È÷½ºÅ¸¹ÎÁ¦
  • antihypertensive drug
    °íÇ÷¾Ð¾à, Ç×°íÇ÷¾ÐÁ¦
  • antimalarial drug
    ¸»¶ó¸®¾Æ¾à, Ç׸»¶ó¸®¾ÆÁ¦
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇÁ¦
  • antiseizure drug
    °æ·Ã¾à, Ç×°æ·ÃÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antitumor agent
    Ç×¾ÏÁ¦
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • health screening
    °Ç°­Áø´Ü°Ë»ç, °Ç°­¼±º°°Ë»ç
  • mass screening
    Áý´Ü°Ë»ç
  • multiphasic screening
    ´Ù´Ü°è¼±º°, ´Ù»ó°ËÁø
  • multiphasic screening test
    ´Ù»ó¼±º°°Ë»ç
  • prescriptive screening
    ó¹æÀû¼±º°¹æ¹ý
  • screening program
    Áý´Ü°ËÁø»ç¾÷, À¯¼Ò°ßÀڹ߰߻ç¾÷
  • screening coordinate recorder
    ÁÖ»ç½ÄÁÂÇ¥±â·Ï±â
  • screening
    °Ë»ö, ¼±º°
  • screening test
    ¼±º°°Ë»ç
  • screening hearing test
    ¼±º°Ã»·Â°Ë»ç
  • adrenergic drug
    ¾Æµå·¹³¯¸°ÀÛ¿ë¾à
  • adverse drug reaction
    ¾à¹°ºÎÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • OTC drug : over-the-counter drug
    ÀϹݸžà.
  • antitumor agent
    Ç×Á¾¾çÁ¦, Ç×Á¾¾ç¹°Áú
  • antitumor agent
    Ç׾Ͼà(ù÷äßå·), Ç×Á¾¾ç(¼º)¾à.
  • antitumor agent
    Ç׾Ͼà(ù÷ å·), Á¦¾Ï¾à(ð¤ å·), Ç×Á¾¾ç(¼º)¾à(ù÷ðþåËàõå·), Ç×Á¾¾ç(¼º)ÀÎÀÚ.
  • antitumor antibiotic
    Ç×Á¾¾ç(¼º) Ç×»ý¹°Áú(¡­(àõ) ù÷ßæÚªòõ).
  • antitumor immunity
    Ç×Á¾¾ç(¼º) ¸é¿ª(¡­Øóæ¹).
  • DDST=Denver developmental screening test
    µ§¹ö¹ß´ÞÁ¶»ç°Ë»ç
  • Denver Developmental Screening Test
    µ§¹ö¹ß´ÞÁ¶»ç°Ë»ç(Û¡Ó¹ðàÞÛËþÞÛ)
  • Denver developmental screening test
    µ§¹ö¹ßÀ°¼±º°¹ý.
  • Falcon assay screening test
    ÆÈÄܺм®¼±º°½ÃÇè
  • antibody screening cells
    Ç×ü¼±º°Ç÷±¸
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • health screening
    °Ç°­Áø´Ü°Ë»ç, °Ç°­¼±º° °Ë»ç.
  • hearing test, screening
    ¼±º°Ã»·Â°Ë»ç
  • population screening
    Áý´Ü°ËÁø(̤ËÀ˧̤).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antitumor agent
    Ç׾Ͼà(ù÷äßå·), Ç×Á¾¾ç(¼º)¾à.
  • antitumor agent
    Ç׾Ͼà(ù÷ å·), Á¦¾Ï¾à(ð¤ å·), Ç×Á¾¾ç(¼º)¾à(ù÷ðþåËàõå·), Ç×Á¾¾ç(¼º)ÀÎÀÚ.
  • antitumor agent
    Ç×Á¾¾çÁ¦, Ç×Á¾¾ç¹°Áú
  • antitumor antibiotic
    Ç×Á¾¾ç(¼º) Ç×»ý¹°Áú(¡­(àõ) ù÷ßæÚªòõ).
  • antitumor immunity
    Ç×Á¾¾ç(¼º) ¸é¿ª(¡­Øóæ¹).
  • cytotoxic antitumor antibody
    ¼¼Æ÷µ¶¼ºÇ×Á¾¾çÇ×ü
  • immunity, antitumor
    Ç×Á¾¾ç¸é¿ª
  • k cell,antitumor
    Ç×Á¾¾ç(ù÷ðþåË)
  • drug dependence ; drug dependency
    ¾à¹°ÀÇÁ¸(¼º).
  • antibody screening cells
    Ç×ü¼±º°Ç÷±¸
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • health screening
    °Ç°­Áø´Ü°Ë»ç, °Ç°­¼±º° °Ë»ç.
  • hearing test, screening
    ¼±º°Ã»·Â°Ë»ç
  • multiphasic health screening
    ´Ù»ó½Ä °Ç°­°ËÁø.
  • multiphasic screening
    ´Ù»ó¼º ¼±º°°Ë»ç.
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antiamebic drug
    ¾Æ¸Þ¹Ù±¸ÃæÁ¦
  • antimalarial drug
    Ç׸»¶ó¸®¾ÆÁ¦
  • mass screening
    Áý´Ü°Ë»ç
  • screening test
    ¼±º°°Ë»ç
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antitumor antibiotics
    Ç×Á¾¾ç Ç×»ýÁ¦(ù÷ðþåËù÷ßæð¥)
  • antitumor antimetabolite
    Ç×Á¾¾ç Ç×´ë»ç¹°(ù÷ðþåËù÷ÓÛÞóÚª)
  • antitumor enzyme
    Ç×Á¾¾ç È¿¼Ò(ù÷ðþåËý£áÈ)
  • antitumor protein
    Ç×Á¾¾ç ´Ü¹éÁú(ù÷ðþåËÓ±ÛÜòõ)
  • drug-detoxication enzyme
    ¾à¹°Çص¶ È¿¼Ò(å·Úªú°Ô¸ý£áÈ) (ÔÒ) drug-metabolizing enzyme
  • drug-metbolizing enzyme
    ¾à¹°´ë»ç È¿¼Ò(å·ÚªÓÛÞóý£áÈ)
  • drug resistance
    ¾à¹° ÀúÇ×(å·Úªî½ù÷)
  • drug-resistance plasmid
    ¾à¹°ÀúÇ×(å·Úªî½ù÷) Çö󽺹̵å (ÔÒ) R plasmid
  • narcotic drug
    ¸¶¾à(ئå·)
  • psychedelic drug
    ȯ°¢Á¦(ü³ÊÆð¥)
  • radiomimetic drug
    ¹æ»ç¼± ¾ç(À¯»ç) ¾à¹°(Û¯ÞÒàÊåÆ(ëºÞÄ)å·Úª)
  • sulfa drug
    ¼³ÆÄÁ¦(ð¥)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antitumor agent
    Ç׾Ͼà, Á¦¾Ï¾à
  • health screening
    °Ç°­Áø´Ü°Ë»ç, °Ç°­¼±º°°Ë»ç
  • screening
    ½ºÅ©¸®ÀÌ´×, ¼±º°¹ý
  • screening test
    ¼±º°°Ë»ç, ¿¹ºñ°Ë»ç
  • drug
    ¾à, ¾à¹°, ¾àÁ¦
  • drug abuse
    ¾à¹°³²¿ë
  • narcotic drug
    ¸¶¾à
  • tuberculostatic drug
    Ç×°áÇÙ¾à
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
DAST drug abuse screening test; drug and alcohol screening test
ROATS rabbit ovarian antitumor serum
DA dark adaptation; dark agouti [rat]; daunomycin; degenerative arthritis; delayed action; Dental Assis...
CD cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise...
DD dangerous drug; data definition; day of delivery; degenerated disc; degenerative disease; delusional...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
DAS-ELISA Double antibody sandwich enzyme-linked immunosorbent assays
EMSA Electromobility shift assays
IEMA immuno-enzymometric assays
LDA Limiting dilution assays
MMA Monocyte monolayer assays
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antitumor agent
    Ç׾Ͼà, Á¦¾Ï ¾à, Ç×Á¾¾ç ¾à, Ç×Á¾¾ç¼º ¾à, Ç×Á¾¾ç ÀÎÀÚ, Ç×Á¾¾ç¼º ÀÎÀÚ
  • antitumor k cell
    Ç×Á¾¾ç k ¼¼Æ÷
  • Denver developmental screening test
    µ§¹ö ¹ßÀ° ¼±º° °Ë»ç, µ§¹ö ¹ßÀ° ¼±º°¹ý
    ¹ßÀ° ºÎÁøÀÌ ÀÖ´Â ¿µ¾Æ³ª ÇÐ·É Àü±â ¾Æµ¿À» ½Äº°ÇÏ´Â °Ë»ç¹ý.
  • screening device
    °Ë»ö ±â±â
  • screening examination
    °£ÀÌ °Ë»ç
  • screening history
    °£ÀÌ º´·Â Á¶»ç
  • screening test
    ¼±º° °Ë»ç, ¿¹ºñ °Ë»ç
  • addicting drug
    ½À°ü¼º ¾à
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸° ÈïºÐ ¾à, ¾Æµå·¹³¯¸°¼º ÈïºÐ¾à, ¾Æµå·¹³¯¸° ÀÚ±ØÁ¦, ¾Æµå·¹³¯¸°¼º ÀÚ±ØÁ¦
  • adverse drug reaction
    ¾à¹°ÀÇ ºÎÀÛ¿ë
  • anesthetic drug
    ¸¶Ãë ¾à
  • antagonistic drug
    ±æÇ× ¾à, ±æÇ×Á¦
  • antiamebic drug
    Ç׾Ƹ޹٠¾à
    ¾Æ¸Þ¹Ù¸¦ »ì¸ê ¶Ç´Â ¹ßÀ°À» ¾ïÁ¦ÇÏ´Â ¾à¹°.
  • antiarrhythmic drug
    Ç׺ÎÁ¤¸ÆÁ¦
  • antibody-drug-cell complex
    Ç×ü ¾à¹° ¼¼Æ÷ º¹ÇÕü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
drug screening assays, antitumour Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumour growth parameters in laboratory animals.
(12 Dec 1998)
drug screening Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.
(12 Dec 1998)
chemiluminescence assays Including a subcategory using bioluminescence (biologically derived chemiluminescence agents), use the generation of light from oxidative chemical reactions as an indicator of the quantity of unbound luminescent labelled antigen. This allows quantitation of unlabelled antigen from patient specimens in a variety of homogeneous (single phase) or heterogeneous (multiple phase) immunoassay techniques.
(05 Mar 2000)
drug-drug interaction The effects that occur when two or more drugs are used together. Such effects include changes of absorption in the digestive tract, changes in rate of the drugs' breakdown in the liver, new or enhanced side effects and changes in the drugs' activity.
(09 Oct 1997)
cancer, colon: screening and surveillance Colon cancer is both preventable and curable. It is preventable by removing precancerous colon polyps. It is curable if early cancer is surgically removed before cancer spread to other parts of the body. Therefore, if screening and surveillance programs were practiced universally, there would be a major reduction in the incidence and mortality of colon cancer.
(12 Dec 1998)
genetic screening The process of testing individuals to find out if they carry genes for certain known genetic diseases, such as sickle cell anaemia.
(09 Oct 1997)
carrier screening Indiscriminate examination of members of a population to detect heterozygotes for serious disorders and counsel about the risks of marriages with other carriers, and by antenatal diagnosis where a married couple are both carriers; often sacrifices precision to simplicity and is most effectively applied to populations known to be at high risk.
(05 Mar 2000)
mass screening Organised periodic procedures performed on large groups of people for the purpose of detecting disease.
(12 Dec 1998)
vision screening Application of tests and examinations to identify visual defects or vision disorders occurring in specific populations, as in school children, the elderly, etc. It is differentiated from vision tests, which are given to evaluate/measure individual visual performance not related to a specific population.
(12 Dec 1998)
multiphasic screening The simultaneous use of multiple laboratory procedures for the detection of various diseases. These are usually performed on groups of people.
(12 Dec 1998)
prenatal screening Screening for the detection of foetal disease, usually by ultrasound examination or by testing amniotic fluid obtained by amniocentesis. Other screening techniques include testing maternal serum and placental biopsy.
(05 Mar 2000)
cytologic screening A screening for the detection of early disease, usually cancer, through microscopic examination of a cellular specimen by inspecting each cell and structure present, usually at ×100 magnification with a mechanical stage, so that all areas are screened; the findings are evaluated and significant abnormalities are flagged (e.g., by dotting the cover slip) for further evaluation by a cytopathologist. This screening is usually performed by a cytotechnologist, but at times is done by automated machine prescreening.
(05 Mar 2000)
screening Examination of people with no symptoms, to detect unsuspected disease.
(16 Dec 1997)
screening audiometry Rapid measurement of the hearing of an individual or a group against a predetermined limit of normalcy; auditory responses to different frequencies presented at a constant intensity level are tested.
(05 Mar 2000)
screening test Any testing procedure designed to separate people or objects according to a fixed characteristic or property.
(05 Mar 2000)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Drug Screening Assays, Antitumor - »õâ Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
    Synonyms : Anti-Cancer Drug Screens, Antitumor Drug Screening Assays, Tumor-Specific Drug Screening Tests, Anti Cancer Drug Screens, Anti-Cancer Drug Screen, Antitumor Drug Screen, Cancer Drug Test, Drug Screen, Anti-Cancer, Drug Screen, Antitumor, Drug Screens, Antitumor
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antitumor
    Á¦¾Ï¼ºÀÇ;Ç×Á¾¾ç¼ºÀÇ
  • screening
    üÁúÇϱâ;½É»ç;°¡¸®±â;Â÷Æä
  • Food and Drug Administration
    ½Äǰ ÀǾ౹(º¸°Ç ±³À° º¹Áö¼ºÀÇ ÀϺÎ)
  • combination drug
    º¹ÇÕ¾à(2Á¾ ÀÌ»óÀÇ Ç×»ý ¹°Áú µîÀÇ È¥ÇÕ¾à)
  • counter drug
    ÀÇ»çÀÇ Ã³¹æ ¾øÀÌ ÆÇ¸ÅµÇ´Â ¾à
  • drug
    ¾à;¾àÁ¦;¾àǰ;¸¶¾à;~¿¡ ¾àÀ»³Ö´Ù;¸¶Ãë½ÃŰ´Ù;¹°¸®°ÔÇÏ´Ù
  • drug addict
    ¸¶¾à Áßµ¶ÀÚ
  • drug buster
    (¹Ì)¸¶¾à ´Ü¼Ó°ü 
  • drug design
    (¾à)¾àÁ¦ ¼³°è(À¯È¿¼ºÀ» ³ôÀ̱â À§ÇÑ Á¾ÇÕÀû °³¹ß °ËÅä
  • drug interaction
    (¾à)¾à¹° »óÈ£ ÀÛ¿ë
  • drug pump
    (ÀÇ)¾à ÆßÇÁ(Ç÷°ü ÁÖ»ç¿ë)
  • fertillity drug
    ÀӽŠÃËÁøÁ¦
  • garbage drug
    ¿ªÈ¿°ú¸¦ ÃÊ·¡Çϱ⠽¬¿î ¸¶¾à(Á¢ÂøÁ¦³ª ½Ã³Ê µî)
  • hard drug
    ½À°ü¼º ¸¶¾à
  • miracle drug
    Ưȿ¾à;¿µ¾à
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á